How much revenue does Torrent Pharmaceuticals make?

Torrent Pharmaceuticals reported 113.17 billion INR in revenue for fiscal year 2025, up 7.1% from 105.62 billion INR in fiscal year 2024. In Q2 2026 revenue was 32.46 billion INR.

Where does Torrent Pharmaceuticals make most of its revenue?

India: 59% of revenue by region in fiscal year 2025, followed by Other Countries (12%).

What companies are similar to Torrent Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sun Pharmaceutical Industries Limited (SUNPHARMA.NS), Zydus Lifesciences Limited (ZYDUSLIFE.NS), Cipla Limited (CIPLA.NS), Mankind Pharma Limited (MANKIND.NS).

Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Stock

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-inte...

At a glance

Torrent Pharmaceuticals reported revenue of 113.17 billion INR for fiscal year 2025, up 7.1% from fiscal year 2024, and net income of 19.11 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 32.46 billion INR, up 14.7% from a year before. India was its largest region in fiscal year 2025, with 59% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.